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Conventional karyotyping detects anomalies in 3e15% of patients with multiple congenital anomalies
and mental retardation (MCA/MR). Whole-genome array screening (WGAS) has been consistently sug-
gested as the ﬁrst choice diagnostic test for this group of patients, but it is very costly for large-scale use
in developing countries. We evaluated the use of a combination of Multiplex Ligation-dependent Probe
Ampliﬁcation (MLPA) kits to increase the detection rate of chromosomal abnormalities in MCA/MR
patients. We screened 261 MCA/MR patients with two subtelomeric and one microdeletion kits. This
would theoretically detect up to 70% of all submicroscopic abnormalities. Additionally we scored the de
Vries score for 209 patients in an effort to ﬁnd a suitable cut-off for MLPA screening. Our results reveal
that chromosomal abnormalities were present in 87 (33.3%) patients, but only 57 (21.8%) were consid-
ered causative. Karyotyping detected 15 abnormalities (6.9%), while MLPA identiﬁed 54 (20.7%). Our
combined MLPA screening raised the total detection number of pathogenic imbalances more than three
times when compared to conventional karyotyping. We also show that using the de Vries score as a cut-
off for this screening would only be suitable under ﬁnancial restrictions. A decision analytic model was
constructed with three possible strategies: karyotype, karyotype þ MLPA and karyotype þ WGAS.
Karyotype þ MLPA strategy detected anomalies in 19.8% of cases which account for 76.45% of the
expected yield for karyotype þWGAS. Incremental Cost Effectiveness Ratio (ICER) of MLPA is three times
lower than that of WGAS, which means that, for the same costs, we have three additional diagnoses with
MLPA but only one with WGAS. We list all causative alterations found, including rare ﬁndings, such as
reciprocal duplications of regions deleted in Sotos and WilliamseBeuren syndromes. We also describe
imbalances that were considered polymorphisms or rare variants, such as the new SNP that confounded
the analysis of the 22q13.3 deletion syndrome.
 2011 Elsevier Masson SAS. Open access under the Elsevier OA license.ee@uol.com.br (F.S. Jehee),
der the Elsevier OA license.1. Introduction
Multiple congenital anomalies and mental retardation (MCA/
MR) comprise a large, heterogeneous group of diseases that affect
approximately 3% of newborns. The ability of conventional kar-
yotyping to detect chromosomal anomalies in newborns varies
considerably, ranging from 3 to 15% depending on patient selection
and the inclusion of Down syndrome in the cohort [1,2]. Using
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hybridization (FISH), Multiplex Ligation-dependent Probe Ampli-
ﬁcation (MLPA) and whole-genome array screening (WGAS) almost
doubles the detection rate of chromosomal abnormalities in MCA/
MR [3e7]. WGAS alone detects 99% of all chromosomal alterations,
and recent reports have suggested that WGAS should replace
conventional karyotyping as the ﬁrst diagnostic test used to detect
chromosomal abnormalities in patients with MCA/MR [2,8e10].
WGAS is more costly than traditional karyotyping, followed by
targeted FISH, but is an attractive alternative because of its
increased clinical effectiveness [11]. The Brazilian government has
included genetic testing in social medical services and the
compulsory package of insurance companies, but the high cost of
these techniques has made implementation difﬁcult in Brazil and
other developing countries. Unfortunately, to identify subtelomeric
imbalances and microdeletions, FISH is also prohibitively expen-
sive. Therefore, the low cost of MLPA makes it a viable alternative
that would substantially increase the identiﬁcation of chromo-
somal alterations.
The aim of this project was to determine the ability of
a combination of MLPA kits to detect chromosomal abnormali-
ties such as submicroscopic microdeletions and subtelomeric
imbalances in a group of MCA/MR patients. Additionally, we
wanted to test the feasibility of this approach for use in routine
diagnosis.
2. Material and methods
2.1. Patients
This was a prospective study including 261 patients with
multiple congenital malformations with or without mental retar-
dation (MCA/MR). Clinical geneticists evaluated all patients prior to
referral to the study. Common aneuploidies, such as trisomies 21,
13, 18 and Turner syndrome, were not included. The ﬁrst 209
patients were assessed for the presence of prenatal growth retar-
dation, postnatal growth abnormalities, facial and non-facial dys-
morphisms, congenital abnormalities and familial occurrence of
mental retardation and were given a de Vries score (a check list for
subtelomeric imbalances) [12]. The de Vries score was used as an
abnormality evaluation, not as criteria for inclusion or exclusion in
molecular screening. The presence and severity of mental retar-
dation could not be determined for all cases because many patients
were neonates or younger than three years old at the time of
referral.
2.2. Methods
All patients were screened with three MLPA kits: two for sub-
telomeric imbalances (P036 and P070) and one for the most
common microdeletion syndromes (P064), which include deletion
22q11.21, Williams, PradereWilli/Angelman, SmitheMagenis, Mill-
ereDieker and deletion 1p36 (MRC-Holland, Amsterdam, The
Netherlands). When needed, conﬁrmatory testing was performed
with kit P356, which is also able to detect microdeletion syndromes
in chromosome 22. The details of regions detected by each kit can be
found at www.mlpa.com. Chromosomal analysis by GTG-banding
was performed by independent offsite cytogenetic laboratories.
MLPA was carried out according to the manufacturer’s instruc-
tions. Initially, electrophoresis and fragment analysis were per-
formed using the Mega-BACE TM 1000 DNA analysis system and
Fragment Proﬁler software version 1.2 (GE Healthcare). Statistical
analyses were carried out using excel spreadsheets developed by
the National Genetics Reference Laboratories (NGRL, Manchester,
UK, www.ngrl.org.uk). During the second phase, electrophoresiswas performed using an ABI 3100 Genetic Analyzer, and data were
analyzed out using GeneMarker software (Softgenetics, www.
softgenetics.com).
Results were considered abnormal when the relative peak
height ratio was below 0.75 or above 1.25. Exceptions were made
for results obtained with probes known to be variable. When
possible, aberrant results were checked by independent reactions
using parental samples in the same reaction batch. The DGV data-
base (http://projects.tcag.ca/variation/) was consulted for all
abnormal probes to determine whether they were located in
regions with known polymorphic copy number variants (CNVs). An
abnormal result was considered causative when it was detected by
both subtelomeric kits and was not present in parental samples.
Inherited subtelomeric alterations were classiﬁed as non-causative
variants and were not considered pathogenic. When an abnor-
mality was detected using a subtelomeric kit and parental DNAwas
not available, the result was considered a) causative when addi-
tional methodologies conﬁrmed the alteration or b) inconclusive
when conﬁrmation could not be performed. For the microdeletion
syndrome kit, results were considered causative when more than
two probes to the same region produced abnormal results. When
abnormal results were obtained with only one probe, the test was
repeated with parental samples to exclude the possibility of
inherited variants. Parents of patients with deletions at 22q11.21
were checked to determine if they were carriers. Conﬁrmation of
the MLPA results by a second independent technique was not
performed for all cases due to ﬁnancial restrictions. The clinical
data of all patients were reviewed on the basis of the anomaly
found and whenever these data were conﬂicting further studies
were performed (see below).
To clarify the economic aspect of the possible strategies used to
diagnose chromosomal rearrangements in MCA/MR, a decision
analytic model was constructed using TreeAge Pro 2011 (TreeAge
Pro Inc, Williamstown, MA, USA). We designed our model with
three possible strategies: karyotype, karyotype þ MLPA and
karyotype þ WGAS. Data from karyotype and karyotype þ MLPA
strategies were taken from our results.
Costs were initially calculated in local currency, Brazilian real
(RS $) and then converted to US dollars (US $) using exchange rate
(US $ 1.00¼ RS $ 1.673). Effectiveness was calculated as the number
of additional diagnoses compared to karyotype.3. Results and discussion
Currently, WGAS is the preferred technique for the diagnosis of
patients with multiple congenital anomalies and mental retardation
(MCA/MR) [10,11]. However, the high cost of whole-genome array
screening makes it unfeasible for many countries. In this study, we
evaluated, the ability of a combination of MLPA kits to detect sub-
telomeric imbalances and commonmicrodeletion syndromes suchas
DiGeorge (deletion22q11.21), deletion 1p36,Williams, PradereWilli/
Angelman, SmitheMagenis and MillereDieker syndromes.
Our cohort of patients included 261 individuals (132 males and
129 females). Referral ages varied from three days to 26 years and 3
months, with a mean age of 6 years and 1 month. Karyotype and
MLPA analyses revealed chromosomal imbalances in 87 (33.3%)
patients (Table 1). Conventional karyotyping detected 17 of the
abnormalities (6.5%), while MLPA identiﬁed 83 (31.8%). Three
abnormalities were detected exclusively by cytogenetics, while 70
imbalances were detected only by MLPA. After analysis of parental
samples and CNV, 24 of the imbalances were considered inherited
non-causative variants. Additionally, the 47 XYY result found in
a newborn male was considered not related to the phenotype. Five
imbalances were considered inconclusive. Therefore, in our total
Table 1
Total results for the screening for chromosomal abnormalities with karyotyping and
MLPA.
Combined
approach
(%) MLPA (%) Karyotyping (%)
Total cohort 261 100.0 261 100.0 217 100.0
Total abnormalities 87 33.3 83 31.8 17 7.8
Inherited variantsa 24 9.2 24 9.2 0 0.0
Not related 1 0.4 1 0.4 1 0.5
Inconclusive 5 1.9 3 1.1 1 0.5
Causative 57 21.8 54 20.7 15 6.9
a Known heterochromatin polymorphisms in karyotype were not recorded.
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phenotype (21.8%).
Conventional karyotyping was performed in 217 patients and
detected 15 causative alterations (6.9%). Using MLPA to screen
patients raised the total detection number of pathogenic chromo-
somal imbalances to 57 (21.8%), which is three times the number
detected by karyotyping.3.1. Causative abnormalities
All 57 causative anomalies are listed in Table 2. Only three
alterations detected by conventional karyotyping were not detec-
ted by MLPA: two de novo apparently balanced translocations inTable 2
Causative abnormalities found in the 261 patients screened.
Patient Karyotype MLPA kit P036
1 46, XX, t(11q;13q) nrl
2 46, XX, t(1;2)(p36.2;q35),
t(6;18)(p11.2;p11.2)
nrl
3 46, XX, add(21q10) nrl
4,5 45, X del Xp/del Xq
6,7 47, XY, þ mar dup 22"p"a
8 6, XX, dup 3pter del 3p/dup 7q
9 46, XY, der(3) del 3p/dup 11q
10 46, XY, del 4p15 del 4p
11 46, XX, del 4qter del 4q
12 46, XX, dup 4qter del 4q/dup 10q
13 46, XY, der(18qþ) del 18q/dup 4q
14 45, X [10]/46, X, þ mar [20] del Xp/del Xq
15 47,XX,þder(9) dup 9p
16 46, XX del 2p
17,18 46, XX or 46, XY del 3p
19 46, XX del 4p/dup18p/del 4qb
20,21 46, XX del 4p
22 46, XX del 5p
23 46, XX del 1q
24 46, XX del 3qc
25 46, XX del 4q/dup 2p
26 46, XX del 6q/dup 14q
27 not available del 10p/dup 9q
28,29 46, XX del 10q
30 46, XY del 18q/dup 8q
31,32 46, XX or 46, XY del 18q/dup 3q
33 not available del 22q
34 46, XY dup 1p/del 22q
35 not available not performed
36,37 46, XXe del 15"p"a
38e49 46, XX or 46, XYe nrl
50e52 46, XXe nrl
53,54 46, XYe nrl
55 46, XY nrl
56 not available nrl
57 not available nrl
a The 13, 14, 15, 21 and 22 p probes target the q arm, close to centromere.
b SNP in probe site, inherited.
c de novo 1.6-Mb interstitial deletion at band 3q29 detected by Affymetrix 100 K SNP
d Breakpoint between probes located at FLJ10782 and TP73.
e For some patients no karyotyping is available because MLPA was the ﬁrst choice ofpatients 1 and 2 and an additional segment in chromosome 21 of
patient 3. As expected, MLPA was important for the characteriza-
tion of derivative and marker chromosomes not identiﬁed by
conventional cytogenetics. This is illustrated by the two cases of cat
eye syndrome (patients 6 and 7), where the signal of both probes to
22"p" (22q11.21) indicated four copies of the region, suggesting
that the marker chromosome was an inverse duplication (22). We
also found that other chromosomes were involved in the imbal-
ances of patients 8, 9, 12 and 13. However, we did not identify the
extra segment present on the short arm of chromosome 21 in
patient 3.
Regarding only patients with normal karyotype, submicroscopic
subtelomeric imbalances were found in 19 patients (7.3%); 11 of
them were pure terminal or cryptic deletions, and the rest were
balanced translocations. The incidence of submicroscopic sub-
telomeric imbalances in our sample did not differ signiﬁcantly from
other studies [13]. The incidence of common microdeletion and
microduplication syndromes identiﬁed was slightly higher than
that of previous studies (24/261; 9.2%), which illustrates that
submicroscopic imbalances may be responsible for a large portion
of chromosomal abnormalities in MCA/MR patients [1,14,15].
Deletion 22q11.21 was the most frequent abnormality found (12/
261e4.6%), representing 21.1% of all alterations. In similar studies
with different selection criteria for patients, detection of the
22q11.21 deletion varied from 0.5% to 2.4% [1,14,15]; in comparison,
the rate in our study is surprisingly high. Interestingly, prior toMLPA kit P070 MLPA kit P064
nrl nrl
nrl nrl
nrl nrl
del Xp/del Xq nrl
dup 22"p"a nrl
del 3p/dup 7q nrl
del 3p/dup 11q nrl
del 4p nrl
del 4q nrl
del 4q/dup 10q not performed
del 18q/dup 4q not performed
del Xp/del Xq nrl
dup 9p nrl
del 2p nrl
del 3p nrl
del 4p/dup18p not performed
del 4p nrl
del 5p nrl
del 1q nrl
nrl nrl
del 4q/dup 2p nrl
del 6q/dup 14q nrl
del 10p/dup 9q nrl
del 10q nrl
del 18q/dup 8q nrl
del 18q/dup 3q nrl
del 22q nrl
dup 1p/del 22q dup 6 probes at 1p36d
del 1p del 7 probes at 1p36
del 15"p"a del 5 probes at 15q11 (Prader/Angelman Syndrome)
nrl del 6 probes in 22q11.23 (DiGeorge Syndrome)
nrl del 6 probes in 7q11.23 (Williams Syndrome)
nrl del 5 probes at 17p11.2 (SmitheMagenis Syndrome)
nrl del 7 probes in 17p13.3 (MillereDieker Syndrome)
nrl dup 3 probes in 5q35.3 (NSD1 gene)
nrl dup 5 probes in 7q11.23 (Williams Syndrome region)
array.
testing.
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22q11.21 deletion. The young age of the patients combinedwith the
diverse clinical expressivity of the 22q11.21 deletion syndromemay
have contributed to this underdiagnosis.
Reciprocal duplications of regions deleted in Sotos and Wil-
liamseBeuren syndromes were found in patients 56 and 57,
respectively, reinforcing the results of Kirchhoff et al. [14], which
found that these microduplications may not be as rare as reported
by Shaffer et al. [15], where only eight duplications of the Wil-
liamseBeuren region and one of the Sotos syndrome region were
found in 8789 patients.
Using two kits instead of one to screen for subtelomeric
imbalances is important to conﬁrm the results from extremely
polymorphic regions. Special care should be taken in cases where
only one kit ﬁnds an MLPA abnormality, which happened quite
frequently in this study. Most single detection imbalances were
inherited and classiﬁed as non-causative variants (see below). De
novo subtelomeric anomalies found with only one kit were
conﬁrmed by other techniques, such as WGAS. Deletion of the
region detected by the 3qter probe, BDH (kit P036), in patient 24
was conﬁrmed by Affymetrix 100 K SNP array. The Affymetrix
genome screening detected a de novo 1.6 Mb interstitial deletion at
band 3q29, which indicated that the breakpoint of this deletionwas
between the two subtelomeric MLPA probes used.
3.2. Inherited non-causative variants
We found inherited variants in twenty-four patients (Table 3).
The copy number of speciﬁc variations in the genome can inﬂuence
clinical symptoms. Additionally, the presence of the same abnor-
mality in a patient and his/her healthy parent may be a result of
incomplete penetrance or imprinting mechanisms. Moreover,
recessive disorders may be revealed by the loss of one allele and the
mutation of the other. However, in this study, we considered sub-
telomeric abnormalities inherited from healthy parents as non-
causative.
When abnormal results were detected, the genomic region
corresponding to each probe was examined for the presence of
CNVs. Determining that probes were located at CNVs was impor-
tant but not sufﬁcient to determine whether the results were
associated with the patient’s phenotype. MLPA imbalances,
particularly deletions, should be interpreted carefully. Firstly,
a deletion detected by MLPA may be a result of hemizygosity or the
presence of a SNP in the probe hybridization site. Secondly, the
extent of the imbalance detected by subtelomeric MLPA is notTable 3
Non causative, false positive, inconclusive or polymorphic abnormalities found in 261 pa
Patient Karyotype MLPA P036a
58 46, XYY dup Xp/dup Xq/dup Yq11
59 46, XY del 7p
60 45, XX, der(13;13)b nrl
61 46, XY del 14q
62 46, XY nrl
63 46, XY nrl
64 46, XX dup 16q
65 46, XY dup 16q
66 46, XX dup 12p
67 46, XY del 12p
68 46, XX del 4q/del 12p
69e77 46, XX or 46, XY del 16p
7883 46, XX or 46, XY del 4q
84,85 46, XX dup 5p
86,87 46, XX or 46, XY nrl
88 46, XX nrl
a With the exception of the X and Y probes and for the 12p RBBP2 probe (kit P070) al
b Parents refused further studies, such as isodisomy.known. Therefore, we cannot assume that alterations found in
patients completely correspond to known alterations in the CNV
database. All probes listed in Table 3, with the exception of 12p
RBBP2 (kit P070), are located at known CNVs. However, as described
below, at least two of the alterations found were due to a SNP in the
probe site and not to deletion of the corresponding CNV.
The 4q deletion found using older versions of kit P036 detected
in both heterozygous and homozygous states in our samples were
due to a SNP in the probe site (MRC-Holland information sheet).
Probes for 2p and 4p in kit P070 have been described as variable by
the manufacturer. Moreover, we detected several alterations that
had never been reported as polymorphic by MLPA users, including
a 16p deletion, a 12p deletion and duplication, a 22q deletion and
a 5p duplication. Each of these new alterations was inherited from
healthy parents. Therefore, the presence of parental samples was
extremely important for interpretation of the data. Unlike previous
studies [3], we did not have problems obtaining parental samples,
which were collected at the same time as the patient’s sample.
We were not able to determine the mechanisms underlying all
the above mentioned variants. It is reasonable to think that dupli-
cations are due to CNVs, but deletions can be caused either by CNVs
or SNPs at the probe sites.
The two deletions detected by the 22q ARSA probe (kit P070) in
patients 86 and 87 were additionally studied. This probe is located
in the region deleted in 22q13.3 syndrome (PhelaneMcDermid
syndrome), an important and well-known mental retardation
syndrome. The two patients, however, did not match the clinical
symptoms of the syndrome. In both cases, the relative peak height
for the ARSA probe was between 0.75 and 0.70 and was therefore
considered abnormal. The relative peak height of the paternal
sample for patient 86 was in the same range. The parental results
for patient 86 were considered normal (the maternal result was
0.95, and paternal result was 0.78). We suspect the presence of
a SNP in the probe site because the peak height for the same probe
in patients 33 and 34, who also had deletions at the 22qter probe
site, was approximately 0.5 (Fig. 1). Follow-up analysis with kit
P356 did not produce any abnormal results for the 17 probes to the
22q13.3 region for patient 86 or 87 or their parents. Furthermore,
the results for the positive control (patient 33) were clearly
abnormal (Fig. 1). Sequence analysis of the ARSA probe site in
patients 86 and 87 and their respective fathers showed the pres-
ence of an undescribed variant NT_011526.7:g.651808C > G (Fig. 1),
which explained the lower signals detected by the P070 reactions.
Although the ARSA probe in kit P070 targets the same region as the
ARSA probe in kit P356, the hybridization site length of the latter istients with multiple congenital anomalies and mental retardation.
MLPA P070a MLPA P064 Conclusion
dup Xp/dup Xq/dup Yq11 nrl non-causative
nrl nrl inconclusive
nrl nrl inconclusive
del 14q nrl inconclusive
del 2p nrl inconclusive
dup Xq nrl inconclusive
dup 16q/del 15q nrl inherited variant
dup 16q/del 4p nrl inherited variant
dup 12p nrl inherited variant
nrl nrl inherited variant
nrl nrl inherited variant
nrl nrl inherited variant
nrl nrl inherited variant
nrl nrl inherited variant
del 22q nrl inherited variant
dup 17q nrl inherited variant
l other probes here in listed are located at known CNVs.
Fig. 1. A, MLPA analyses, with subtelomeric kit P070, showing abnormal results for the ARSA probe at 22q13.3 in patient 86 (peak ratio 0,70) and patient 33 (peak ratio 0,5). B.
Follow-up analysis with 22q kit P356 shows normal results for patient 86 and the deletion of all 17 probes to the 22q13.3 region for patient 32. C. Sequence analysis of the ARSA
probe site in patient 86 depicting the exact position of the C to G change in probe sequence (above).
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may explain why normal results were obtained for all individuals
that were tested with kit P356 (MRC-Holland, personal
communication).
Had we used the 0.70 and 1.30 threshold values for normal
MLPA results we would not have considered the above ﬁndings
abnormal. After this study we have a better knowledge of our
population’s variants and may consider broadening the threshold
values to decrease false positive results.
3.3. Inconclusive ﬁndings
Five results were considered inconclusive. A Robertsonian
translocation between chromosomes 13 in patient 60 does not
explain her clinical ﬁndings. Further studies, such as a test for
isodisomy, were offered but were refused.We also considered three
imbalances detected by MLPA to be inconclusive because we could
not prove they were de novo without parental samples (patients
61e63). Both subtelomeric kits detected a 14q imbalance for
patient 61, which suggests a deletion rather than a SNP in the target
region of each probe. The two probes targetMTA1, which is mapped
at a CNV that has already been described as being deleted in healthy
controls. Patient 63 has a duplication that maps to pseudoautoso-
mal region Xqter/Yq12. Surprisingly, a duplication was detected by
the probe speciﬁc for VAMP7 from kit P070, which maps to thegenomic position 57,680 kb (build 36.3), but was not detected by
the VAMP7 probe from kit P036 that maps 4 kb proximal to the
probe from kit P070. An InDel located at Yq12 (57,670,868e
57,671,032 bp) is duplicated in some controls from the DGV data-
base. It is possible that the VAMP7 probe from kit P070 maps inside
this InDel. We could not determine whether results obtained using
the VAMP7 probe caused diseasewithout also checking the status of
the parents. Patient 62 had a deletion of 2p that was detected by the
ACP1 probe from kit P070, which was intriguing because the
deletion detected by the P070 kit probe is only 2 kb distal to the site
detected by the normal ACP1 probe from kit P036. Duplications of
the entire ACP1 gene are described for normal controls in DGV, but
deletions have not previously been described. On the other hand,
a deletion of ACP1 has been found in several healthy controls in
a Dutch population using the ACP1 probe from kit P036 (MRC-
Holland information sheet). In the case of patient 62, we know the
mother was not a carrier of the deletion, but we were unable to
obtain a paternal sample for testing.
The last inconclusive case was patient 59, with a deletion of the
region detected by the 7pter CENTA1 probe (kit P036). This deletion
was not conﬁrmed by Agilent 44 K oligo array. Parental samples did
not show the sameMLPA abnormality. Due to the low quality of the
original sample and parental refusal of a new collection, we
repuriﬁcate patient’s DNA before MLPA and array testing. It is
possible that our inconsistent results were due to the DNA quality.
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check if he has a SNP at the probe site. Therefore, this result was
also considered inconclusive.
3.4. de Vries score
A de Vries score was collected for 209 patients. The mean score
for all samples was 4.8. The mean de Vries score for patients with
causative abnormalities and for patients with normal/inconclusive/
non-causative abnormalities was 5.0 and 4.7, respectively. Patients
with karyotype abnormalities had a higher mean de Vries score of
5.5 compared to 4.8 in the group with submicroscopic imbalances.
Likewise, patients with subtelomeric abnormalities had a higher
mean de Vries score of 5.3 compared to 4.4 for patients with inter-
stitial microdeletions ormicroduplications. The differences inmean
scoresmay be reﬂective of the original purpose of the de Vries score,
which was to deﬁne a check list for the study of submicroscopic
subtelomeric imbalances. Table 4 shows thenumber andpercentage
of patients within each de Vries score. It was not beneﬁcial to use
a cut-off value as a deciding factor forwhether to include a patient in
the screening.We detected abnormalities in 22.7% of patientswith a
de Vries score of up to 6, with a substantial increase of detected
abnormalities in patients with a de Vries score of 7 or higher.
However, with a cut-off of 7, we would have been screening
signiﬁcantly fewer patients and excluding almost 80% of the
detected chromosomal abnormalities. Taking ﬁnancial restrictions
into account, we would suggest using MLPA in patients with a de
Vries score of at least 4, which would detect 83% of abnormalities.
3.5. Decision analytic model
In our economic analysis we only considered 217 cases that had
both karyotype andMLPA results since it is impossible to determine
if karyotype could identify the anomaly when only MLPA was
performed. Our purpose was to compare karyotype, a routine and
less expensive strategy, with a suggested strategy karyotype þ
MLPA and with karyotype þWGAS.
We calculated tests costs including only reagents and import
taxes for a private laboratory setting. Based on that, karyotype cost
was US$ 14.94, MLPA, US$ 235.67 (for the three kits combined),
sequencing, US$ 97.43 and WGAS, US$ 1141.88.
Our results, shown in Fig. 2, provided probabilities to diagnose
(Dx) the anomaly when only karyotype was performed (15 Dx/217
casese0.069) andwhenboth karyotypeþMLPAwere performed (42
Dx/217 casese0.194). Moreover, we added on our model, all addi-
tional testswe used after karyotypeþMLPA.WeperformedWGAS in
two cases and sequenced two other cases. Only one case was diag-
nosed after WGAS. Even though WGAS and sequencing did not
contribute to solve all investigated cases after karyotype þ
MLPA,we included these data to precisely calculate all costs involvedTable 4
Sensitivity and speciﬁcity of the de Vries score for the ﬁrst 209 patients screened.
de Vries Score Total Number of patients with
causative anomalies
0 209 47
1 208 47
2 205 46
3 194 44
4 161 39
5 113 27
6 68 14
7 32 10
8 18 6
9 4 2
10 4 2in this strategy. To compare with WGAS strategy, we used our data
on detection rate for chromosome aberrations, 6.9% and the data
from a review of 29 array-based studies of unselected MCA/MR
patients that yieldw19% pathogenic aberrations [2]. It was establish
therefore that the probability of diagnosis with karyotype þWGAS
was 6.9% þ 19% ¼ 25.9% (0.259). The karyotyping þ MLPA strategy
detected anomalies in 19.8% of caseswhich account for 76.45% of the
expected detecting yield for karyotype þWGAS (25.9%).
In clinical practice in Brazil, karyotype is the current diagnostic
test used to identify chromosomal abnormalities. So, we calculated
Incremental Cost Effectiveness Ratio (ICER) to compare the strate-
gies karyotypeþMLPAand karyotypeþWGASwith karyotype. ICER
gives us the incremental cost necessary to provide one more diag-
nosis. Our analysis shows that when MLPA (plus all conﬁrmatory
tests, such as the twoWGAS and sequencing) is added to karyotype
there is an incremental cost of US$ 19.11/diagnosis (ICER ¼ 19.11).
When WGAS is performed, the incremental cost raises up to US$
60.13/diagnosis (ICER¼ 60.13), whichmeans that costs necessary to
obtain one more diagnosis are more than three times higher when
using WGAS when compared to the combined MLPA strategy.
For the costs of the combined MLPA strategy we used the
number of reactions needed to diagnose one patient that was 5.6
reactions, which includes three MLPA kits, parental samples,
negative controls and repetition due to technical failure (results not
shown). On the other hand, costs for WGAS were calculated for
a single Affymetrix 100 K SNP array testing, not including parental
testing or technical failure.
In total, 44 patients had no conventional cytogenetic analyses
due to clinical suspicion of a microdeletion syndrome or other
reasons. We believe our overall results would not have changed
signiﬁcantly had karyotyping been performed for all patients. We
do not expect a large number of anomalies in the patients with
normal MLPA results and no available karyotype. The chances of
patients having an interstitial imbalance, a balanced translocation
or mosaicism is approximately 15% [2].
Although conﬁrmatory tests using other technologies such as
FISH or WGAS are valuable, in most cases, MLPA results in combi-
nation with karyotyping and/or revision of clinical ﬁndings were
sufﬁcient for diagnosis.
MLPA is easy to perform and produces good, reliable results. We
had estimated that we could detect 55e72.5% of all submicroscopic
abnormalities found in MCA/MR with MLPA. Subtelomeric imbal-
ances account for 30e40% of the total chromosomal abnormalities,
and interstitial microdeletions and microduplications represent
50e65%. Half of these are located in regions of the most common
microdeletion syndromes listed above, and 3% are consistent with
complex rearrangements or mosaicism [1,2,15]. By screening for
imbalances in all subtelomeres and regions with the most common
microdeletion syndromes, we can detect all subtelomeric imbal-
ances (30e40%) and half of the interstitial microdeletions and% patients with alteration within
the score group (speciﬁcity)
% patients with alteration within
abnormality group (sensitivity)
225 100.0
22.6 100.0
22.4 97.9
22.7 93.6
24.2 83.0
23.9 57.4
20.6 29.8
31.3 21.3
33.3 12.8
50.0 4.3
50.0 4.3
Fig. 2. Decision Analytic Model. Open square represents a decision node, open circle a transition probability, open triangle a terminal node. Dx, diagnosis. Se, sequencing. Each
terminal node has a correlated cost and effectiveness. Costs were calculated depending on tests performed in each branch until terminal node and effectiveness were determined as
additional diagnoses compared to karyotype every 100 cases.
F.S. Jehee et al. / European Journal of Medical Genetics 54 (2011) e425ee432 e431microduplications (25e32.5%) in patients with MCA/MR. Indeed,
our decision analytic model showed that we were able to detect
76.45% of the total chromosomal abnormalities expected
(karyotype þWGAS).
Economic models are important to help health professionals to
take decisions based on available strategies. The mathematical
analysis together with socio economic characteristics of the country
is fundamental when a new strategy is considered to be taken,
especially in developing countries where resources are limited.
In conclusion, the combination of three MLPA kits to screen for
the most frequent submicroscopic imbalances is a valuable
resource for the detection of abnormalities in MCA/MR patients.
MLPA is an effective alternativewhenWGAS is unavailable andmay
increase genetic diagnosis of chromosomal imbalances up to four
times. We recommend the analysis of parental samples whenever
available to minimize false positive results. Careful analysis should
be carried out for each patient when no other conﬁrmatory test can
be provided. MLPA is more efﬁcient when patient and parental
samples are collected at the same time and when there is close
communication between the clinic and laboratory.
Acknowledgments
We are grateful for the collaboration of our patients and their
parents. We thank Drs. Carla Rosenberg and Ana C. V. Krepischi for
the Agilent 60 KWGAS experiment. We also thank Salomão e Zoppi
Medicina Diagnóstica for the kind use of its facilities. This work was
supported by FAPESP (Fundação de Amparo à Pesquisa do Estado
de São Paulo), CEPID (Centro de Pesquisa, Inovação e Difusão)
and CNPq (Conselho Nacional de Desenvolvimento Cientíﬁco e
Tecnológico).
References
[1] A. Rauch, J. Hoyer, S. Guth, C. Zweier, C. Kraus, C. Becker, M. Zenker,
U. Huffmeier, C. Thiel, F. Ruschendorf, P. Nurnberg, A. Reis, U. Trautmann,
Diagnostic yield of various genetic approaches in patients with unexplained
developmental delay or mental retardation, Am. J. Med. Genet. Part A 140 A
(2006) 2063e2074.[2] R. Hochstenbach, E. van Binsbergen, J. Engelen, A. Nieuwint, A. Polstra,
P. Poddighe, C. Ruivenkamp, B. Sikkema-Raddatz, D. Smeets, M. Poot, Array
analysis and karyotyping: workﬂow consequences based on a retrospective
study of 36,325 p.tients with idiopathic developmental delay in the
Netherlands, Eur. J. Med. Genet. (2009 Apr 9).
[3] A.P. Stegmann, L.M. Jonker, J.J. Engelen, Prospective screening of patients with
unexplained mental retardation using subtelomeric MLPA strongly increases
the detection rate of cryptic unbalanced chromosomal rearrangements, Eur. J.
Med. Genet. 51 (2) (2008 MareApr) 93e105. Epub 2007 Oct 18.
[4] B.B. de Vries, R. Winter, A. Schinzel, C. van Ravenswaaij-Arts, Telomeres:
a diagnosis at the end of the chromosomes, J. Med. Genet. 40 (2003) 385e398.
[5] C. Shaw-Smith, R. Redon, L. Rickman, M. Rio, L. Willatt, H. Fiegler, H. Firth,
D. Sanlaville, R. Winter, L. Colleaux, M. Bobrow, N.P. Carter, Microarray based
comparative genomic hybridisation (array-CGH) detects submicroscopic
chromosomal deletions and duplications in patients with learning disability/
mental retardation and dysmorphic features, J. Med. Genet. 41 (2004)
241e248.
[6] A.C. Krepischi-Santos, A.M. Vianna-Morgante, F.S. Jehee, M.R. Passos-Bueno,
J. Knijnenburg, K. Szuhai, W. Sloos, J.F. Mazzeu, F. Kok, C. Cheroki, P.A. Otto,
R.C. Mingroni-Netto, M. Varela, C. Koiffmann, C.A. Kim, D.R. Bertola,
P.L. Pearson, C. Rosenberg, Whole-genome array-CGH screening in undiag-
nosed syndromic patients: old syndromes revisited and new alterations,
Cytogenet. Genome Res. 115 (3e4) (2006) 254e261.
[7] D.L. Bruno, D. Ganesamoorthy, J. Schoumans, A. Bankier, D. Coman,
M. Delatycki, M.R. Gardner, M. Hunter, P.A. James, P. Kannu, G. McGillivray,
N. Pachter, H. Peters, C. Rieubland, R. Savarirayan, I.E. Scheffer, L. Shefﬁeld,
T. Tan, S.M. White, A. Yeung, Z. Bowman, C. Ngo, K. Choy, V. Cacheux, L. Wong,
D. Amor, H.R. Slater, Detection of cryptic pathogenic copy number variations
and constitutional loss of heterozygosity using high resolution SNP microarray
analysis in 117 p.tients referred for cytogenetic analysis and impact on clinical
practice, J. Med. Genet. (2008 Nov 17).
[8] A.C. Gijsbers, J.Y. Lew, C.A. Bosch, J.H. Schuurs-Hoeijmakers, A. van Haeringen,
N.S. den Hollander, S.G. Kant, E.K. Bijlsma, M.H. Breuning, E. Bakker,
C.A. Ruivenkamp, A new diagnostic workﬂow for patients with mental
retardation and/or multiple congenital abnormalities: test arrays ﬁrst, Eur. J.
Hum. Genet. (2009 May 13).
[9] M. Kriek, J. Knijnenburg, S.J. White, C. Rosenberg, J.T. den Dunnen, G.-
J.B. van Ommen, H.J. Tanke, M.H. Breuning, K. Szuhai, Diagnosis of genetic
abnormalities in developmentally delayed patients: a new strategy
combining MLPA and array-CGH, Am. J. Med. Genet. Part A 143 A (2007)
610e614.
[10] D.T. Miller, M.P. Adam, S. Aradhya, L.G. Biesecker, A.R. Brothman, N.P. Carter,
D.M. Church, J.A. Crolla, E.E. Eichler, C.J. Epstein, W.A. Faucett, L. Feuk,
J.M. Friedman, A. Hamosh, L. Jackson, E.B. Kaminsky, K. Kok, I.D. Krantz,
R.M. Kuhn, C. Lee, J.M. Ostell, C. Rosenberg, S.W. Scherer, N.B. Spinner,
D.J. Stavropoulos, J.H. Tepperberg, E.C. Thorland, J.R. Vermeesch,
D.J. Waggoner, M.S. Watson, C.L. Martin, D.H. Ledbetter, Consensus statement:
chromosomal microarray is a ﬁrst-tier clinical diagnostic test for individuals
with developmental disabilities or congenital anomalies, Am. J. Hum. Genet.
86 (5) (2010 May 14) 749e764 (Review).
F.S. Jehee et al. / European Journal of Medical Genetics 54 (2011) e425ee432e432[11] D.A. Regier, J.M. Friedman, C.A. Marra, Value for money? Array genomic
hybridization for diagnostic testing for genetic causes of intellectual disability,
Am. J. Hum. Genet. 86 (5) (2010 May 14) 765e772. Epub 2010 Apr 15.
[12] B.B. de Vries, S.M. White, S.J. Knight, R. Regan, T. Homfray, I.D. Young, M. Super,
C. McKeown, M. Splitt, O.W. Quarrell, A.H. Trainer, M.F. Niermeijer, S. Malcolm,
J. Flint, J.A. Hurst, R.M. Winter, Clinical studies on submicroscopic subtelomeric
rearrangements: a checklist, J. Med. Genet. 38 (3) (2001 Mar) 145e150.
[13] L. Rooms, E. Reyniers, R.F. Kooy, Subtelomeric rearrangements in the mentally
retarded: a comparison of detection methods, Hum. Mutat. 25 (6) (2005 Jun)
513e524.[14] M. Kirchhoff, A.M. Bisgaard, T. Bryndorf, T. Gerdes, MLPA analysis for a panel
of syndromes with mental retardation reveals imbalances in 5.8% of patients
with mental retardation and dysmorphic features, including duplications of
the Sotos syndrome and WilliamseBeuren syndrome regions, Eur. J. Med.
Genet. 50 (1) (2007 Jan-Feb) 33e42.
[15] L.G. Shaffer, B.A. Bejjani, B. Torchia, S. Kirkpatrick, J. Coppinger, B.C. Ballif,
The identiﬁcation of microdeletion syndromes and other chromosome
abnormalities: cytogenetic methods of the past, new technologies for the
future, Am. J. Med. Genet. Part C Semin. Med. Genet. 145C (2007)
335e345.
